An Open-label, Two-period Fixed-sequence Study to Investigate the Effect of Multiple Doses of Aleglitazar on a Single Dose of Digoxin in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2016
At a glance
- Drugs Aleglitazar (Primary) ; Digoxin
- Indications Arrhythmias; Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Roche
- 23 May 2013 Actual end date changed from Apr 2013 to Jan 2013 as reported by ClinicalTrials.gov.
- 14 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Oct 2012 New trial record